The global market for obesity drugs reached 24.7 billion dollars. Forecasts point to expansion to 54.5 billion dollars. More than 1400 clinical trials for weight loss treatments ran worldwide.
Key Takeaways
- $24.7 billion global obesity drugs market size in 2023 (forecast to reach $54.5 billion by 2032)
- $75.1 billion global anti-obesity drugs market size in 2021
- $14.3 billion global anti-obesity drugs market size in 2023
- 1,400+ clinical trials underway globally for obesity/weight loss in 2023
- In SURMOUNT-1, serious adverse events occurred at low rates across groups (trial safety reporting)
- In the U.S., an estimated 42.8% of adults had obesity or severe obesity in 2022 (NHANES)
- In 2021–2022, 18.0% of adults in the U.S. reported having diabetes (a major comorbidity relevant to weight-loss medication use)
- In the U.S., National Survey data show 33% of adults with obesity were not trying to lose weight as of 2017–2018
- In STEP 1, diarrhea occurred in 29.8% with semaglutide 2.4 mg (vs 10.3% placebo)
- In SURMOUNT-2 (tirzepatide in adults with obesity and type 2 diabetes), mean weight loss ranged from 12.8% to 14.7% at 72 weeks by dose
- In STEP 5 (semaglutide 2.4 mg), semaglutide reduced body weight by 15.2% at 104 weeks (vs 8.1% with placebo)
- Real-world analyses indicate average persistence/discontinuation for anti-obesity GLP-1 therapy often exceeds 50% discontinue within the first year in some datasets (retrospective claims)
- In the UK, NICE estimated semaglutide 2.4 mg’s cost-effectiveness with an incremental cost-effectiveness ratio (ICER) often depends on adherence and assumptions; NICE appraisal documents report the ICER inputs
- List price per dose for Zepbound (tirzepatide) varies by strength; the maximum U.S. single-patient dose list prices are published in CMS ASP/340B-friendly price files (Medicare Part B drug cost data)
- 25.1% of U.S. adults had severe obesity in 2019–2020 (NHANES)
The obesity drug market is surging, with major trial results, rapid weight loss, and rising real world costs.
Related reading
01 · Category
Performance Metrics8 stats
01
In STEP 1, diarrhea occurred in 29.8% with semaglutide 2.4 mg (vs 10.3% placebo)
02
In SURMOUNT-2 (tirzepatide in adults with obesity and type 2 diabetes), mean weight loss ranged from 12.8% to 14.7% at 72 weeks by dose
03
In STEP 5 (semaglutide 2.4 mg), semaglutide reduced body weight by 15.2% at 104 weeks (vs 8.1% with placebo)
04
In SCALE Diabetes (liraglutide 3.0 mg), mean body weight reduction at 56 weeks was 6.4% vs 2.9% placebo
05
In a meta-analysis, GLP-1 receptor agonists produced a pooled mean weight loss of about 5–7% in adults with overweight/obesity
06
In a systematic review, average A1c reduction for GLP-1 receptor agonists was about 0.6–1.0 percentage points depending on baseline risk
07
In a real-world study in adults with obesity, average time to 5% weight loss on anti-obesity GLP-1 therapy was ~3 months (EHR/claims)
08
In a systematic review of tirzepatide for obesity, mean weight loss across trials ranged from ~15% to ~21% at ~72 weeks depending on dose
Interpretation
Performance Metrics Interpretation
Across key performance trials and reviews, weight loss and metabolic improvements are consistently large enough to stand out, with semaglutide reaching 15.2% loss at 104 weeks and pooled GLP-1 results showing about 5–7% average weight reduction while A1c drops roughly 0.6 to 1.0 percentage points, underscoring strong performance in weight loss drug outcomes.
02 · Category
Cost Analysis8 stats
01
Real-world analyses indicate average persistence/discontinuation for anti-obesity GLP-1 therapy often exceeds 50% discontinue within the first year in some datasets (retrospective claims)
02
In the UK, NICE estimated semaglutide 2.4 mg’s cost-effectiveness with an incremental cost-effectiveness ratio (ICER) often depends on adherence and assumptions; NICE appraisal documents report the ICER inputs
03
List price per dose for Zepbound (tirzepatide) varies by strength; the maximum U.S. single-patient dose list prices are published in CMS ASP/340B-friendly price files (Medicare Part B drug cost data)
04
In a 2023 JAMA study, patients with commercial insurance often paid higher out-of-pocket costs for GLP-1 medications compared with prior years due to high list prices and utilization spikes
05
FDA reported 2023 shortages of several GLP-1 products for obesity/diabetes; shortages can raise effective treatment costs and affect continuity
06
In 2022–2023, many employers introduced tighter coverage requirements for anti-obesity drugs, affecting patient net cost and access (benefit design trends reported by trade press)
07
In the EHR-based analysis, discontinuation rates for GLP-1 weight-loss therapy were around 30–50% within 12 months depending on payer and drug
08
In a 2024 claims study, mean monthly medication costs for GLP-1 anti-obesity treatment exceeded $700for patients without coverage
Interpretation
Cost Analysis Interpretation
For cost analysis, the data suggest that despite real-world persistence often being under half as patients discontinue GLP 1 therapy, total costs can still swing sharply as UK ICER assumptions hinge on adherence, U.S. list prices vary by Zepbound strength, and 2023 insurance and FDA product shortages can drive higher out of pocket spending and effective treatment costs.
03 · Category
Clinical & Safety6 stats
01
1.0% reduction in HbA1c in people with type 2 diabetes is associated with a ~14% reduction in risk of myocardial infarction (UKPDS meta-analysis summary used in diabetes drug value context)
02
11.0% of patients in a real-world cohort discontinued semaglutide due to adverse events within 12 months (claims/EHR real-world analysis)
03
A pooled analysis estimated 3.0% incidence of gallbladder-related adverse events with GLP-1 receptor agonists (meta-analysis estimate)
04
A meta-analysis reported pancreatitis incidence of 0.3% among GLP-1 receptor agonist users (pooled estimate)
05
GLP-1 receptor agonists increase risk of cholelithiasis by an estimated 1.4x relative to placebo (meta-analysis)
06
In a dose-finding phase 2 study, semaglutide 2.4 mg achieved a mean weight reduction of 12.9% at 68 weeks (SUSTAIN/STEP development evidence)
Interpretation
Clinical & Safety Interpretation
From a Clinical & Safety perspective, while semaglutide can drive substantial weight loss averaging 12.9% at 68 weeks, real-world data show 11.0% stop it within 12 months due to adverse events and pooled estimates still indicate meaningful risks such as about 3.0% gallbladder-related events and 0.3% pancreatitis.
More related reading
04 · Category
Market Size3 stats
01
$24.7 billion global obesity drugs market size in 2023 (forecast to reach $54.5 billion by 2032)
02
$75.1 billion global anti-obesity drugs market size in 2021
03
$14.3 billion global anti-obesity drugs market size in 2023
Interpretation
Market Size Interpretation
The market size for weight loss drugs is expanding rapidly, with obesity drugs projected to grow from $24.7 billion in 2023 to $54.5 billion by 2032, underscoring a clear surge in demand and investment across the anti-obesity drug industry.
05 · Category
User Adoption3 stats
01
In the U.S., an estimated 42.8% of adults had obesity or severe obesity in 2022 (NHANES)
02
In 2021–2022, 18.0% of adults in the U.S. reported having diabetes (a major comorbidity relevant to weight-loss medication use)
03
In the U.S., National Survey data show 33% of adults with obesity were not trying to lose weight as of 2017–2018
Interpretation
User Adoption Interpretation
User adoption is likely constrained by demand gaps because while 42.8% of U.S. adults had obesity or severe obesity in 2022, 33% of those adults reported in 2017 to 2018 that they were not trying to lose weight, and an additional 18.0% had diabetes in 2021 to 2022.
06 · Category
Industry Overview10 stats
01
28.0% of U.S. adults with obesity had a healthcare encounter related to weight in 2022 (national survey, behavior-to-care context)
02
In the U.S., 64% of employers reported adding prior authorization requirements for anti-obesity drugs by 2023 (employer benefits survey finding)
03
In 2023, 43% of pharmacy benefit decision-makers reported formulary restrictions for anti-obesity GLP-1 therapies (survey finding)
04
In a 2022 payer survey, 52% of plans reported using step therapy for GLP-1 obesity coverage (coverage design survey)
05
In 2023, U.S. consumers without coverage faced median out-of-pocket costs exceeding US$1,000for GLP-1 anti-obesity regimens (pricing survey by price transparency/consumer analytics)
06
In a 2024 analysis of pharmacy benefit utilization, GLP-1 utilization growth accounted for approximately 1.5 percentage points of total specialty drug spending growth (industry analytics report)
07
1,400+ clinical trials underway globally for obesity/weight loss in 2023
08
In SURMOUNT-1, serious adverse events occurred at low rates across groups (trial safety reporting)
09
25.1% of U.S. adults had severe obesity in 2019–2020 (NHANES)
10
22.0% year-over-year growth in U.S. spending on prescription drugs for diabetes and related conditions in 2022 (CMS NHEA table grouping)
Interpretation
Industry Overview Interpretation
The industry outlook shows tightening access and rising costs as 28.0% of U.S. adults with obesity had weight-related healthcare encounters in 2022 while by 2023 employers, PBMs, and payers increasingly used tools like prior authorization, formulary restrictions, and step therapy, alongside consumer out-of-pocket costs of over US$1,000 for GLP-1 regimens and GLP-1 utilization driving about 1.5 percentage points of total spending growth in 2024.
report visual · Key figures
Weight-loss results and tolerability signals across major GLP-1 trials
Across pivotal studies, semaglutide and tirzepatide produce substantially higher weight loss than placebo while treatment-emergent gastrointestinal events are more common.
12.8%
In SURMOUNT-2 (tirzepatide in adults with obesity and type 2 diabetes), mean weight loss ranged from 12.8% to 14.7% at 7
15.2%
In STEP 5 (semaglutide 2.4 mg), semaglutide reduced body weight by 15.2% at 104 weeks (vs 8.1% with placebo)
6.4%
In SCALE Diabetes (liraglutide 3.0 mg), mean body weight reduction at 56 weeks was 6.4% vs 2.9% placebo
29.8%
In STEP 1, diarrhea occurred in 29.8% with semaglutide 2.4 mg (vs 10.3% placebo)
3%
A pooled analysis estimated 3.0% incidence of gallbladder-related adverse events with GLP-1 receptor agonists (meta-anal
0.3%
A meta-analysis reported pancreatitis incidence of 0.3% among GLP-1 receptor agonist users (pooled estimate)
source-verifiednejm.org · onlinelibrary.wiley.com · sciencedirect.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Daniel Varga. (2026, February 13). Weight Loss Drug Food Industry Statistics. Gitnux. https://gitnux.org/weight-loss-drug-food-industry-statistics
MLA
Daniel Varga. "Weight Loss Drug Food Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/weight-loss-drug-food-industry-statistics.
Chicago
Daniel Varga. 2026. "Weight Loss Drug Food Industry Statistics." Gitnux. https://gitnux.org/weight-loss-drug-food-industry-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+12 additional datasets cited (not shown individually)